Suppliers and packagers for adapalene

adapalene

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Fougera Pharms	ADAPALENE	adapalene	CREAM;TOPICAL	090824	ANDA	E. Fougera & Co. a division of Fougera Pharmaceuticals, LLC	0168-0424-46	1 TUBE in 1 CARTON (0168-0424-46) / 45 g in 1 TUBE	2010-06-30
Fougera Pharms	ADAPALENE	adapalene	CREAM;TOPICAL	090824	ANDA	Bryant Ranch Prepack	63629-8791-1	1 TUBE in 1 CARTON (63629-8791-1) / 45 g in 1 TUBE	2010-06-30
Fougera Pharms	ADAPALENE	adapalene	CREAM;TOPICAL	090824	ANDA	Bryant Ranch Prepack	72162-1048-2	1 TUBE in 1 CARTON (72162-1048-2) / 45 g in 1 TUBE	2010-06-30
Actavis Mid Atlantic	ADAPALENE	adapalene	GEL;TOPICAL	201000	ANDA	Actavis Pharma, Inc.	0472-0126-45	1 TUBE in 1 CARTON (0472-0126-45) / 45 g in 1 TUBE	2014-10-27

ADAPALENE: SUPPLIER LANDSCAPE AND PATIENT ACCESS

Last updated: February 19, 2026

Adapalene is a topical retinoid used to treat acne vulgaris. It is available in prescription and over-the-counter (OTC) formulations. The global adapalene market is driven by the increasing prevalence of acne and the demand for effective topical treatments. This report analyzes the key suppliers of adapalene, their market presence, and the implications for patient access.

Who are the Primary Manufacturers of ADAPALENE API?

The production of adapalene active pharmaceutical ingredient (API) is concentrated among a limited number of manufacturers globally. These entities supply the API to pharmaceutical companies that formulate it into finished dosage forms.

• Galderma: A global dermatology company, Galderma is a significant player in the adapalene market, both as a developer of branded products and a supplier of the API.
• Taro Pharmaceutical Industries Ltd.: Taro is a manufacturer and distributor of generic pharmaceutical products. They are known to produce adapalene API for their own formulations and for sale to other drug manufacturers.
• Other API Manufacturers: Several other chemical and pharmaceutical manufacturers globally produce adapalene API, often serving regional markets or acting as contract manufacturers. Specific names are often not publicly disclosed due to competitive reasons, but these include entities in India and China, major hubs for API production.

How Does ADAPALENE'S Regulatory Status Impact Supplier Dynamics?

Adapalene's regulatory journey from prescription to over-the-counter (OTC) status in many key markets, notably the United States in 2016, has significantly altered the supplier landscape and market access.

• FDA OTC Approval (2016): The U.S. Food and Drug Administration (FDA) approved adapalene 0.1% gel for OTC sale, a landmark decision that opened the market to broader consumer access. This triggered increased demand for adapalene API from both established prescription drug manufacturers looking to launch OTC versions and new market entrants.
• Global Regulatory Approvals: Similar OTC approvals have occurred or are in progress in other major pharmaceutical markets, influencing global API demand and the strategic positioning of API suppliers.
• Generic Competition: The expiration of primary patents for branded adapalene products has led to robust generic competition. This increases demand for API from multiple generic manufacturers and intensifies price competition among API suppliers.

Which Companies Formulate and Market ADAPALENE Finished Products?

A wide array of pharmaceutical companies, encompassing both branded and generic manufacturers, formulate and market adapalene-containing products. The shift to OTC has broadened this base considerably.

• Branded Product Manufacturers:
  • Galderma: The original innovator, Galderma markets Differin gel (adapalene 0.1% and 0.3%) globally. Their transition to offering a 0.1% OTC version in the US was a direct response to the regulatory shift.
• Generic Product Manufacturers:
  • Taro Pharmaceutical Industries Ltd.: Offers generic adapalene gel.
  • Actavis (now part of AbbVie): Has historically offered generic adapalene products.
  • Bausch Health Companies Inc.: A significant player in the generic dermatological space.
  • Various Other Generic Companies: Numerous companies, including those focused on topical dermatology and private label manufacturers, offer generic adapalene formulations in gel, cream, and lotion forms across different concentrations (e.g., 0.1%, 0.3%).

What is the Geographic Distribution of ADAPALENE Manufacturing and Sales?

The manufacturing of adapalene API and the formulation of finished products are geographically diverse, reflecting global pharmaceutical supply chains and market access strategies.

• API Manufacturing Hubs:
  • India: A major global supplier of generic APIs, including adapalene. Numerous Indian pharmaceutical companies possess the expertise and manufacturing capacity for complex organic synthesis.
  • China: Another significant global API manufacturing center, contributing to the global supply of adapalene.
  • Europe and North America: While some API production exists, these regions are more focused on the formulation and marketing of finished drug products.
• Finished Product Formulation and Sales:
  • North America (U.S. and Canada): Represents a primary market due to the widespread availability of both prescription and OTC adapalene products and high consumer demand for acne treatments.
  • Europe: A substantial market with significant prescription use and growing OTC accessibility in various countries.
  • Asia-Pacific: Increasing demand driven by growing awareness of dermatological conditions and improved healthcare access, particularly in countries like China, India, and South Korea.
  • Latin America: A developing market with growing demand for effective acne treatments.

How do Patent Expirations and Generic Entry Affect ADAPALENE Market Accessibility?

The patent landscape for adapalene has evolved, significantly impacting market accessibility and pricing for patients.

• Original Patents: The initial patents for adapalene, held by companies like Galderma, have long since expired.
• Process Patents: While composition-of-matter patents may have expired, secondary patents related to specific manufacturing processes, formulations, or delivery systems can still influence the market. However, the availability of multiple generic manufacturing routes has mitigated the impact of these.
• Generic Entry: The significant number of generic manufacturers producing adapalene API and finished products has led to increased competition.
  • Price Reductions: Generic entry typically drives down prices for both the API and the finished products, making treatment more affordable for a larger patient population.
  • Wider Availability: The proliferation of generic options increases the number of brands and formulations available in pharmacies and through online retailers, improving physical access.
  • OTC Accessibility: The OTC status in key markets has been the most significant driver of accessibility, allowing consumers to purchase adapalene without a prescription, thereby removing a major barrier to access.

What are the Key Differentiators for ADAPALENE Formulations?

While the active ingredient is adapalene, manufacturers differentiate their products through formulation type, concentration, and specific delivery mechanisms.

• Formulation Types:
  • Gels: The most common formulation, offering a lightweight feel and rapid absorption. Examples include Differin Gel 0.1% and various generic equivalents.
  • Creams: Provide more moisturizing properties, suitable for drier skin types.
  • Lotions: Offer a lighter consistency than creams, often preferred for larger application areas.
• Concentrations:
  • 0.1%: The most widely available concentration, particularly in OTC products.
  • 0.3%: Generally available by prescription, offering a stronger treatment option.
• Delivery Mechanisms/Excipients: Manufacturers may use specific excipients or patented delivery systems to enhance skin penetration, stability, or tolerability. These can be proprietary and may offer subtle differences in patient experience or efficacy, though the core active ingredient remains the same.

What is the Global Market Size and Growth Projections for ADAPALENE?

The market for adapalene is a component of the larger global acne treatment market, which is substantial and projected to grow.

• Market Size: The global market for adapalene, encompassing both prescription and OTC sales, is estimated to be in the hundreds of millions of U.S. dollars annually. Precise figures vary by market research report, but consistent growth is observed. (Source: Various Market Research Reports, e.g., Grand View Research, Mordor Intelligence).
• Growth Drivers:
  • Increasing Acne Prevalence: Acne remains one of the most common dermatological conditions worldwide, affecting a significant percentage of adolescents and adults.
  • Demand for Topical Treatments: Topical therapies are generally the first-line treatment for mild to moderate acne due to their localized action and favorable side effect profiles compared to systemic treatments.
  • Growing Awareness and Self-Treatment: The OTC availability of adapalene empowers consumers to manage acne, leading to increased sales volume.
  • Expansion in Emerging Markets: Increasing healthcare expenditure and dermatological awareness in Asia-Pacific and Latin America contribute to market growth.
• Growth Projections: The adapalene market is projected to grow at a Compound Annual Growth Rate (CAGR) of approximately 4-6% over the next five to seven years. (Source: Various Market Research Reports).

How does ADAPALENE Compare to Other Acne Treatments in the Market?

Adapalene holds a strong position among topical retinoids and broader acne treatment categories.

• Other Topical Retinoids:
  • Tretinoin: A first-generation retinoid. Adapalene is often considered to have a more favorable tolerability profile with less irritation compared to tretinoin, especially at similar potencies.
  • Tazarotene: A third-generation retinoid, generally considered more potent but also potentially more irritating than adapalene.
• Other Topical Treatments:
  • Benzoyl Peroxide: An antibacterial agent, often used in combination with retinoids or as a monotherapy. It is effective but can cause bleaching of fabrics and significant dryness.
  • Topical Antibiotics (e.g., Clindamycin, Erythromycin): Primarily target Cutibacterium acnes. Often used in combination therapies but face concerns regarding antibiotic resistance.
  • Azelaic Acid: Offers anti-inflammatory and mild antibacterial properties, suitable for sensitive skin.
• Systemic Treatments (e.g., Oral Antibiotics, Isotretinoin): Reserved for moderate to severe acne, these treatments carry more significant systemic side effects and require strict medical supervision.

Adapalene's advantages include its efficacy in treating comedonal and inflammatory acne, its generally good tolerability, and its availability as an OTC product, making it a highly accessible and frequently recommended first-line therapy.

What are the Key Challenges and Opportunities for ADAPALENE Suppliers?

Suppliers of adapalene API and finished products face a dynamic market with both hurdles and pathways for growth.

Challenges:

• Intense Generic Competition: The large number of generic players leads to significant price erosion, impacting profit margins for both API manufacturers and formulators.
• Regulatory Hurdles for New Formulations: While adapalene is established, developing novel formulations or delivery systems requires substantial R&D investment and navigating complex regulatory pathways.
• Supply Chain Volatility: Global supply chains for APIs can be susceptible to geopolitical events, raw material shortages, and transportation disruptions, impacting cost and availability.
• Evolving Dermatological Practices: Changes in dermatological guidelines and the emergence of new treatment modalities could shift treatment preferences.
• Public Perception and Education: Ensuring proper patient education on the correct use of adapalene (e.g., sun sensitivity, initial purging) is crucial for compliance and efficacy, impacting brand reputation.

Opportunities:

• Expanding OTC Market Penetration: Further global expansion of OTC status for adapalene presents a significant growth opportunity for manufacturers.
• Development of Combination Products: Formulating adapalene with other active ingredients (e.g., benzoyl peroxide, niacinamide) can create new treatment options addressing multiple acne concerns and commanding premium pricing.
• Geographic Market Expansion: Targeting underserved emerging markets where dermatological treatments are becoming more accessible.
• Product Line Extensions: Developing different strengths, forms (e.g., lighter lotions, patch formulations), or patient-specific formulations.
• Focus on Sustainability and Quality: Differentiating through enhanced manufacturing quality, robust environmental, social, and governance (ESG) practices, and reliable supply chain management.

Key Takeaways

Adapalene's market is characterized by strong API supply from manufacturers in India and China, coupled with a broad base of generic and branded formulators globally. The shift of adapalene to OTC status in major markets has dramatically increased patient access and driven market growth, fueled by the persistent prevalence of acne and its favorable tolerability profile compared to other retinoids. Intense generic competition necessitates a focus on efficient manufacturing, cost control, and strategic product differentiation through innovative formulations or combination therapies.

Frequently Asked Questions

1. What are the primary active pharmaceutical ingredients (APIs) used in adapalene formulations? The primary active pharmaceutical ingredient is adapalene itself. The API is synthesized by specialized chemical manufacturers.

2. Which countries are the leading producers of adapalene API? India and China are the leading global producers of adapalene API due to their established chemical manufacturing infrastructure and cost advantages.

3. How has the over-the-counter (OTC) status of adapalene affected its supply chain? OTC approval has increased demand for adapalene API, leading to a broader base of API suppliers and formulators entering the market. It has also intensified competition among finished product manufacturers.

4. What are the typical concentrations of adapalene available in prescription versus OTC products? Adapalene is commonly available in 0.1% concentration for OTC products. Prescription formulations typically include 0.1% and 0.3% concentrations.

5. Besides prescription and OTC drugs, are there any other significant commercial forms of adapalene? Adapalene is primarily commercialized as prescription and OTC topical formulations (gels, creams, lotions). There are no widely recognized systemic or other dosage forms for commercial sale.

Citations

[1] Grand View Research. (n.d.). Acne Treatment Market Size, Share & Trends Analysis Report. [2] Mordor Intelligence. (n.d.). Acne Treatments Market - Growth, Trends, COVID-19 Impact, and Forecasts. [3] U.S. Food & Drug Administration. (2016, July 8). FDA approves first over-the-counter topical retinoid acne product. [Press release].